FACTORS ASSOCIATED WITH THE USE OF IMMUNE CHECKPOINT INHIBITORS IN OLDER ADULTS WITH METASTATIC NON-SMALL CELL LUNG CANCER AND PRE-EXISTING AUTOIMMUNE DISEASE: A SEER-MEDICARE STUDY

被引：0
|
作者：
Gohil, S. [1 ]
Chen, H. [2 ]
Lewis, W. E. [3 ]
Trivedi, M. [2 ]
Aparasu, R. R. [2 ]
Johnson, M. L. [2 ]
机构：
[1] Univ Houston, Coll Pharm, Durham, NC USA
[2] Univ Houston, Coll Pharm, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD75
引用
收藏
页码：S234 / S234
页数：1
相关论文
共 50 条
  • [1] Factors associated with the use of immune checkpoint inhibitors in adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study
    Gohil, Shrey
    Chen, Hua
    Lewis, Whitney E.
    Trivedi, Meghana
    Aparasu, Rajender R.
    Johnson, Michael L.
    JOURNAL OF GERIATRIC ONCOLOGY, 2024, 15 (08)
  • [2] Use of Immune Checkpoint Inhibitors in Patients with Advanced Lung Cancer and Pre-Existing Autoimmune Diseases
    Cytryn, S.
    Efuni, E.
    Velcheti, V.
    Sandigursky, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S726 - S727
  • [3] Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
    Alexander, Swetha
    Swami, Umang
    Kaur, Aneet
    Gao, Yubo
    Fatima, Munazza
    Ginn, Meredith M.
    Stein, Jill E.
    Grivas, Petros
    Zakharia, Yousef
    Singh, Namrata
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (12)
  • [4] Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer
    Nakanishi, Yu
    Masuda, Takeshi
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Tsutani, Yasuhiro
    Iwamoto, Hiroshi
    Okada, Morihito
    Hattori, Noboru
    Fujitaka, Kazunori
    Miyata, Yoshihiro
    Hamada, Hironobu
    RESPIRATORY INVESTIGATION, 2019, 57 (05) : 451 - 459
  • [5] Exposure patterns of immune checkpoint inhibitors among older Medicare beneficiaries with non-small cell lung cancer
    Bates, Benjamin
    Rua, Melanie
    Kania, Brooke
    Jiang, Alex
    Setoguchi, Soko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 342 - 343
  • [6] Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults
    Rawad Elias
    Joshua Morales
    Carolyn Presley
    Current Oncology Reports, 2017, 19
  • [7] Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults
    Elias, Rawad
    Morales, Joshua
    Presley, Carolyn
    CURRENT ONCOLOGY REPORTS, 2017, 19 (09)
  • [8] Safety profiles in the use of immune checkpoint inhibitors by patients with cancer and pre-existing autoimmune diseases
    Freitas, Julia de Almeida Santos
    Neto, Marinho Marques da Silva
    de Lima, Cleverton Kleiton Freitas
    Sorte, Ney Cristian Amaral Boa
    Bendicho, Maria Teresita
    Santos, Anibal de Freitas
    MEDICINA CLINICA, 2025, 164 (02): : 53 - 60
  • [9] Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer
    Youn, Bora
    Trikalinos, Nikolaos A.
    Mor, Vincent
    Wilson, Ira B.
    Dahabreh, Issa J.
    CANCER, 2020, 126 (05) : 978 - 985
  • [10] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
12345